Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Lemieux, Julie
  • Goss, Paul E
  • Parulekar, Wendy R
  • Ingle, James N
  • Pritchard, Kathleen I
  • Robert, Nicholas J
  • Muss, Hyman
  • Gralow, Julie
  • Strasser-Weippl, Kathrin
  • Brundage, Michael Donald
  • Whelan, Kate
  • Tu, Dongsheng
  • Whelan, Timothy

publication date

  • June 20, 2016